During his seven years at AbbVie, Kyle Holen has helped create the company’s development design center. The much-admired unit uses big data and predictive analytics to inform clinical research decisions and operationalize trials around the world.

Holen’s efforts have helped evolve the decision-making process in AbbVie’s clinical programs. Among the innovations he’s championed are the creation of synthetic control arms for single-arm studies, the use of machine learning to better predict site and country performance and the introduction of wearables, sensors and other devices into clinical trials.

Prior to joining AbbVie, Holen worked at Abbott as a medical director. Before that, he was an associate professor of oncology at the University of Wisconsin-Madison.

Holen is bullish on the role technology will play in healthcare’s continued evolution. “There is so much potential for AI in our field,” he told

MM&M earlier this year. “From predicting efficacy or safety parameters to picking the best countries or sites to minimizing protocol amendments, almost everything we do can be improved by the use of advanced data analytics.”